BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs

TerminatedOBSERVATIONAL
Enrollment

3

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

April 22, 2021

Study Completion Date

April 22, 2021

Conditions
MelanomaCancer
Interventions
DIAGNOSTIC_TEST

Blood sample collection

Whole venous blood of participants will be collected in EDTA tubes (max. 10 mL) at baseline, before start of first immunotherapy round. The Belgian Red Cross will perform serological blood group diagnostics, and molecular RBC typing.

Trial Locations (1)

9000

University Hospital Gent, Ghent

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Jessa Hospital

OTHER

collaborator

University Hospital, Antwerp

OTHER

collaborator

Algemeen Ziekenhuis Maria Middelares

OTHER

collaborator

GZA Ziekenhuizen Campus Sint-Augustinus

OTHER

collaborator

AZ Sint-Jan AV

OTHER

collaborator

AZ Nikolaas

OTHER

collaborator

AZ Sint-Lucas Gent

OTHER

collaborator

AZ Sint-Lucas Brugge

OTHER

collaborator

General Hospital Groeninge

OTHER

collaborator

OLV van Lourdes Hospital Waregem

UNKNOWN

collaborator

AZ Damiaan

UNKNOWN

collaborator

AZ Delta

OTHER

collaborator

ASZ Aalst

OTHER

collaborator

Belgian Red Cross

OTHER

lead

University Hospital, Ghent

OTHER